VEGF receptor
Introduction[edit]
The Vascular Endothelial Growth Factor Receptor (VEGFR) is a type of receptor tyrosine kinase that plays a crucial role in the regulation of angiogenesis, the process by which new blood vessels form from pre-existing vessels. VEGFRs are primarily expressed on endothelial cells, which line the interior surface of blood vessels, and are activated by binding to vascular endothelial growth factor (VEGF) ligands.
Structure[edit]
VEGFRs are transmembrane proteins that consist of an extracellular domain, a single transmembrane helix, and an intracellular tyrosine kinase domain. The extracellular domain is responsible for binding to VEGF ligands and is composed of seven immunoglobulin-like domains. The intracellular domain contains the kinase activity necessary for signal transduction.
Types of VEGF Receptors[edit]
There are three main types of VEGF receptors:
- VEGFR-1 (Flt-1): This receptor has a high affinity for VEGF-A and is involved in the regulation of angiogenesis and vascular permeability.
- VEGFR-2 (KDR/Flk-1): This is the principal mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF.
- VEGFR-3 (Flt-4): Primarily involved in lymphangiogenesis, the formation of lymphatic vessels.
Function[edit]
Upon binding of VEGF to its receptor, VEGFR undergoes dimerization and autophosphorylation of specific tyrosine residues in the intracellular domain. This activation triggers a cascade of downstream signaling pathways, including the PI3K/AKT pathway, the MAPK/ERK pathway, and the PLCγ pathway, which collectively promote endothelial cell proliferation, migration, and survival.
Clinical Significance[edit]
VEGFRs are critical targets in the treatment of various diseases characterized by abnormal blood vessel growth, such as cancer, age-related macular degeneration, and diabetic retinopathy. Inhibitors of VEGFR, such as sunitinib and sorafenib, are used as therapeutic agents to block angiogenesis in tumors, thereby inhibiting tumor growth and metastasis.
